Market Overview:
The global alpha mannosidosis treatments market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of alpha mannosidosis, rising awareness about the disease, and advancements in treatment options. The global alpha mannosidosis treatments market is segmented by type into bone marrow transplant (BMT) and enzyme replacement therapy (ERT). The BMT segment is expected to account for a larger share of the market in 2018 owing to its higher efficacy as compared to ERT. By application, the hospitals segment is expected to account for a larger share of the market in 2018 owing to increased accessibilities and affordability of treatments in this sector. Geographically, North America dominates the global alpha mannosidosis treatments market followed by Europe and Asia Pacific.
Product Definition:
Alpha mannosidosis is a rare lysosomal storage disease caused by a deficiency of the enzyme alpha-mannosidase. The lack of this enzyme results in the accumulation of mannose-rich oligosaccharides in cells, tissues, and organs. This build-up can lead to progressive damage to various body systems. There is no cure for alpha mannosidosis and treatment focuses on managing symptoms and preventing further deterioration.
– Enzyme replacement therapy: This involves receiving injections of alpha-mannosidase derived from human or animal sources on a regular basis.
– Diet modifications: A diet that is low in mannose may help to reduce the amount of oligosaccharides that accumulate in the body.
Bone Marrow Transplant (BMT):
Bone marrow transplant (BMT) is a procedure to replace diseased or damaged bone marrow by retrieving the healthy cells from another person's body and placing them in the patient's body. The most common diseases that require BMT are myelodysplastic syndrome, chronic myelogenous leukemia, acute lymphoblastic leukemia, and stem cell deficiency.
Enzyme Replacement Therapy (ERT):
Enzyme replacement therapy (ERT) is a treatment used for Alpha mannosidosis. It works by replacing the damaged or absent enzymes that are responsible for breaking down proteins. The treatment aims to reduce the amount of damage caused to various organs such as liver, kidney, and spleen by reducing their ability to function properly.
Application Insights:
Based on application, the market is segmented into hospitals and specialty clinics. Hospitals held the largest share of over 70.0% in 2017 owing to availability of advanced healthcare facilities for patients suffering from mannosidosis across the globe. In addition, hospital-based care is generally preferred over home care due to better access to medical specialists and experienced nurses who can provide better treatment at a lower cost as compared with specialized clinics or hospitals.
The specialty clinic segment is expected to witness lucrative growth during forecast years due largely in part that these types of clinics have greater flexibility than hospitals when it comes down to providing personalized treatment options for their patients based on their specific needs which are not always feasible within a standard health facility setting.
Regional Analysis:
North America dominated the global market in 2017 owing to favorable healthcare infrastructure, high adoption of advanced therapies and increasing prevalence of rare diseases. Moreover, presence of key players such as Pfizer Inc.; Biogen Inc.; and Novartis AG is also expected to drive growth over the forecast period.
Asia Pacific is expected to witness lucrative growth during the forecast period due to rising disposable income coupled with growing awareness about available treatment options for patients suffering from rare disorders. In addition, increase in number of collaborations between pharmaceutical companies and government organizations for conducting clinical trials will boost revenue generation in this region. For instance, Novartis AG has entered into a collaboration with China CDC (China Center for Disease Control & Prevention) Foundation for conducting research studies on MMD disease management program across China (Novartis). Such initiatives are anticipated propel regional market development during the forecast period.
Growth Factors:
- Increasing prevalence of Alpha Mannosidosis
- Growing awareness about the disease
- Rising demand for better and innovative treatments
- Technological advancements in the field of medical treatment
- Availability of government funding and support
Scope Of The Report
Report Attributes
Report Details
Report Title
Alpha Mannosidosis Treatments Market Research Report
By Type
Bone Marrow Transplant (BMT), Enzyme Replacement Therapy (ERT)
By Application
Hospitals, Specialty Clinic
By Companies
Chiesi Farmaceutici
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
235
Number of Tables & Figures
165
Customization Available
Yes, the report can be customized as per your need.
Global Alpha Mannosidosis Treatments Market Report Segments:
The global Alpha Mannosidosis Treatments market is segmented on the basis of:
Types
Bone Marrow Transplant (BMT), Enzyme Replacement Therapy (ERT)
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Specialty Clinic
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Chiesi Farmaceutici
Highlights of The Alpha Mannosidosis Treatments Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Bone Marrow Transplant (BMT)
- Enzyme Replacement Therapy (ERT)
- By Application:
- Hospitals
- Specialty Clinic
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Alpha Mannosidosis Treatments Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There is no cure for alpha mannosidosis, but there are treatments available that can help improve the patient's quality of life. Treatment options may include supportive care, medication therapy, and surgery. Some patients may require a combination of treatment options to achieve optimal results.
Some of the key players operating in the alpha mannosidosis treatments market are Chiesi Farmaceutici.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Alpha Mannosidosis Treatments Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Alpha Mannosidosis Treatments Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Alpha Mannosidosis Treatments Market - Supply Chain
4.5. Global Alpha Mannosidosis Treatments Market Forecast
4.5.1. Alpha Mannosidosis Treatments Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Alpha Mannosidosis Treatments Market Size (000 Units) and Y-o-Y Growth
4.5.3. Alpha Mannosidosis Treatments Market Absolute $ Opportunity
5. Global Alpha Mannosidosis Treatments Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Alpha Mannosidosis Treatments Market Size and Volume Forecast by Type
5.3.1. Bone Marrow Transplant (BMT)
5.3.2. Enzyme Replacement Therapy (ERT)
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Alpha Mannosidosis Treatments Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Alpha Mannosidosis Treatments Market Size and Volume Forecast by Application
6.3.1. Hospitals
6.3.2. Specialty Clinic
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Alpha Mannosidosis Treatments Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Alpha Mannosidosis Treatments Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Alpha Mannosidosis Treatments Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Alpha Mannosidosis Treatments Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Alpha Mannosidosis Treatments Demand Share Forecast, 2019-2026
9. North America Alpha Mannosidosis Treatments Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Alpha Mannosidosis Treatments Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Alpha Mannosidosis Treatments Market Size and Volume Forecast by Application
9.4.1. Hospitals
9.4.2. Specialty Clinic
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Alpha Mannosidosis Treatments Market Size and Volume Forecast by Type
9.7.1. Bone Marrow Transplant (BMT)
9.7.2. Enzyme Replacement Therapy (ERT)
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Alpha Mannosidosis Treatments Demand Share Forecast, 2019-2026
10. Latin America Alpha Mannosidosis Treatments Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Alpha Mannosidosis Treatments Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Alpha Mannosidosis Treatments Market Size and Volume Forecast by Application
10.4.1. Hospitals
10.4.2. Specialty Clinic
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Alpha Mannosidosis Treatments Market Size and Volume Forecast by Type
10.7.1. Bone Marrow Transplant (BMT)
10.7.2. Enzyme Replacement Therapy (ERT)
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Alpha Mannosidosis Treatments Demand Share Forecast, 2019-2026
11. Europe Alpha Mannosidosis Treatments Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Alpha Mannosidosis Treatments Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Alpha Mannosidosis Treatments Market Size and Volume Forecast by Application
11.4.1. Hospitals
11.4.2. Specialty Clinic
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Alpha Mannosidosis Treatments Market Size and Volume Forecast by Type
11.7.1. Bone Marrow Transplant (BMT)
11.7.2. Enzyme Replacement Therapy (ERT)
11.8. asis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Alpha Mannosidosis Treatments Demand Share, 2019-2026
12. Asia Pacific Alpha Mannosidosis Treatments Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Alpha Mannosidosis Treatments Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Alpha Mannosidosis Treatments Market Size and Volume Forecast by Application
12.4.1. Hospitals
12.4.2. Specialty Clinic
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Alpha Mannosidosis Treatments Market Size and Volume Forecast by Type
12.7.1. Bone Marrow Transplant (BMT)
12.7.2. Enzyme Replacement Therapy (ERT)
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Alpha Mannosidosis Treatments Demand Share, 2019-2026
13. Middle East & Africa Alpha Mannosidosis Treatments Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Alpha Mannosidosis Treatments Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Alpha Mannosidosis Treatments Market Size and Volume Forecast by Application
13.4.1. Hospitals
13.4.2. Specialty Clinic
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Alpha Mannosidosis Treatments Market Size and Volume Forecast by Type
13.7.1. Bone Marrow Transplant (BMT)
13.7.2. Enzyme Replacement Therapy (ERT)
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Alpha Mannosidosis Treatments Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Alpha Mannosidosis Treatments Market: Market Share Analysis
14.2. Alpha Mannosidosis Treatments Distributors and Customers
14.3. Alpha Mannosidosis Treatments Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Chiesi Farmaceutici
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. COMPANY2
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. COMPANY3
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. COMPANY4
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. COMPANY5
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
